Live tape
Top 8, mentions 7d14,333GOOGL2,869 mentions▲ +0.04NVDA2,215 mentions▲ +0.05AMD1,940 mentions▲ +0.08QQQ1,751 mentions▲ +0.05AAPL1,729 mentions▲ +0.05SPY1,560 mentions▲ +0.06TSLA1,164 mentions▲ +0.06SPCX1,105 mentions▲ +0.05

Equity · Healthcare

IMNM

NASDAQ

Immunome (IMNM)

22.31 USD +0.52% vs prior close
Immunome, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers. We hold too few licensed daily closes of our own for IMNM to draw a line in its place.

Track this symbol on TradingView
Market cap
2.5B USD
Revenue, year to Dec 2025
6.9M USD
EPS, diluted, year to Dec 2025
−2.43 USD
52-week range
8 USD – 27 USD
Avg volume
333.7K

as of Jul 17, 2026

Have Immunome (IMNM) insiders bought or sold shares recently?

In the 90 days to 9 Nov 2026, Immunome insiders reported 4 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 5 Jun 2026.

Form 4, 90 days to 9 Nov 2026, newest reported trade 11 Sep 2026

Buys 0Sells 4Net sold $2.53MOther filings 2

Have Immunome (IMNM) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
11 Sep 2026Higgins JackChief Scientific OfficerSell13,200334K USD
12 Aug 2026Barchas IsaacDirectorSell11,048301K USD
11 Aug 2026Barchas IsaacDirectorSell62,2911.6M USD
10 Aug 2026Barchas IsaacDirectorSell10,125264K USD
Sold4 open-market sales96,664$2.53M
2 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Immunome (IMNM) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
11 Sep 2026Higgins JackChief Scientific OfficerOption exercise18,00024K USD
11 Sep 2026Higgins JackChief Scientific OfficerGift8,800

Which funds hold Immunome (IMNM)?

6 of the 45 institutional funds we track reported a Immunome position for the quarter ended 30 Jun 2026 — a combined 22.6M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Immunome (IMNM)?
FundPositionSharesValueShares q/q
Marshall WaceTrimmed500,53710.6M USD−66.2%
Renaissance TechnologiesAdded251,1025.3M USD+264.4%
Citadel AdvisorsAdded224,0794.7M USD+179.4%
Baker Bros. AdvisorsNew position55,3061.2M USD
Two Sigma InvestmentsNew position23,941507K USD
AQR Capital ManagementTrimmed11,780250K USD−37.1%
Balyasny Asset ManagementExited
Millennium ManagementExited

What has been filed or recorded for Immunome (IMNM)?

The filings we hold for Immunome, newest first: 4 fails-to-deliver days, 6 quarterly earnings reports, 2 annual reports and 5 reported financial figures, the latest dated 08 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Immunome (IMNM)?
And
08 Oct 2026Fails to deliverShares failed to deliver2,425 shares46K USD notional · 0.002% of shares out
07 Oct 2026Fails to deliverShares failed to deliver30,220 shares584K USD notional · 0.027% of shares out
01 Oct 2026Fails to deliverShares failed to deliver4,069 shares88K USD notional · 0.004% of shares out
30 Sep 2026Fails to deliverShares failed to deliver4,100 shares90K USD notional · 0.004% of shares out
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.65 USD
30 Jun 2026FinancialsTotal assets565.4M USDat period end
30 Jun 2026FinancialsTotal equity525.1M USDat period end
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.48 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −2.43 USDRevenue $7M
31 Dec 2025FinancialsRevenue6.9M USDfiscal year
31 Dec 2025FinancialsNet income−212.4M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−2.43 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.65 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.50 USDRevenue $4M
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.52 USDRevenue $3M
31 Dec 2024Annual reportFY 2024 reportedEPS −5.00 USDRevenue $9M
30 Sep 2024Quarterly earningsQ3 2024 reportedEPS −0.78 USDRevenue $3M

Immunome (IMNM): frequently asked questions

From live data
2.5B

What is Immunome’s market cap?

Immunome is worth 2.5B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

6.9M

What is Immunome’s revenue?

Immunome reported revenue of 6.9M USD for the year ended 31 Dec 2025, as filed with the SEC. See Filings

4 sales

Have Immunome insiders bought or sold shares recently?

In the 90 days to 9 Nov 2026, Immunome insiders reported 4 open-market sales and no purchases (SEC Form 4); none has bought on the open market since 5 Jun 2026. A further 2 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

6 of 45

Which funds own Immunome?

6 of the 45 funds we track reported a Immunome position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Marshall Wace, Renaissance Technologies and Citadel Advisors. See Funds

−0.65

When did Immunome last report earnings?

Immunome last reported earnings on 30 Jun 2026 for Q2 2026, with EPS of −0.65 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Jun 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings